Form 4: Precigen Director Boosts Stake with Stock, RSUs, Options

Precigen Director Cesar L. Alvarez acquired common stock, restricted stock units, and stock options on March 10, 2026, increasing his beneficial ownership.

Summary

• Director Cesar L. Alvarez acquired 17,806 shares of Precigen common stock at $3.51 per share.
• The common stock acquisition was in lieu of an annual retainer of $62,500.
• Alvarez also received 35,612 Restricted Stock Units (RSUs), which represent a contingent right to receive one share of common stock and vest in full on March 10, 2027.
• Additionally, Alvarez was granted options to purchase 41,073 shares of common stock with an exercise price of $3.51, exercisable immediately and expiring on March 10, 2036.
• Following these transactions, Alvarez beneficially owns 711,070 shares of common stock, 35,612 RSUs, and 41,073 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's increased equity stake, particularly through direct stock acquisition and long-term incentives, suggests confidence in the company's future.

Positives

• A director increasing their stake in the company through stock and options can signal confidence in future performance.
• The issuance of stock in lieu of a cash retainer aligns director interests with shareholders, promoting long-term value creation.

Future Outlook

The vesting schedule for the Restricted Stock Units and the ten-year expiration date of the stock options provide a future timeline for potential share ownership and exercise, indicating a long-term incentive for the director to contribute to the company's success.

Industry Context

StockSavvy.ai notes that insider buying, especially by a director, can be interpreted by the market as a positive signal regarding the company's future prospects, particularly in the biotechnology sector where long-term development and regulatory milestones are critical.

Comparison to Industry Standards

• Director compensation often includes a mix of cash and equity, with equity components like stock and options designed to align director interests with shareholder value creation.
• The grant of RSUs with a one-year vesting period and options with a ten-year term is a common structure for long-term incentive plans in the biotech industry, similar to practices at companies like Moderna or BioNTech, aiming to retain key personnel and incentivize sustained performance.

Stakeholder Impact

• Shareholders: May view the director's increased stake as a positive indicator of management confidence, potentially influencing stock price.

Next Steps

• The 35,612 Restricted Stock Units will vest in full on March 10, 2027.
• The 41,073 stock options can be exercised at any time between March 10, 2026, and March 10, 2036.

Key Dates

Recommendation

While a director increasing their stake is a positive signal of confidence, a Form 4 filing alone does not provide sufficient fundamental information (e.g., financial performance, strategic updates) to warrant a 'buy' recommendation. It primarily indicates insider sentiment, suggesting a 'hold' is appropriate pending further comprehensive analysis of the company's financials and strategic direction.

Keywords

Precigen, PGEN, Cesar L. Alvarez, Director, Insider Trading, Form 4, Stock Acquisition, Restricted Stock Units, Stock Options, Equity Compensation